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Available online 26 December 2014Background: In the absence of controlled, parallel-group studies, statistical methods developed to
estimate treatment effects in patients receiving alternative/rescue treatment in clinical trials may
be used to estimate the effects of multiple sclerosis (MS) therapy switch using available clinical
trial data.
Objective: To use TRANSFORMS data and parametric models to assess the time to first confirmed
relapse in MS patients who switched from intramuscular interferon β-1a (IFNβ-1a IM) 30 μg/mL
once weekly to oral fingolimod 0.5 or 1.25 mg once daily vs. remaining on IFNβ-1a IM.
Methods: Post hoc analyses were conducted using data from the intent-to-treat population. The
Branson and Whitehead switch model with iterative parameter estimation was used to estimate
the ratio of the observed time to first confirmed relapse over the estimated time.
Results: Log-linear regression model results showed that fingolimod 0.5 and 1.25 mg prolonged
time to relapse, with an estimated median time to first relapse of 5.07 years (P = 0.0026 vs.
IFNβ-1a IM) and 4.11 years (P = 0.0113), respectively, versus 2.26 years with IFNβ-1a IM. The
estimated ratio of observed time to first confirmed relapse to the estimated time had the patient
remained on IFNβ-1a IM was 2.09 (95% CI, 1.45–3.04) for switching to fingolimod 0.5 mg and
1.84 (95% CI, 1.30–2.65) for switching to fingolimod 1.25 mg.
Conclusion: During the extension, time to first confirmed relapse was approximately doubled in
patients switching from IFNβ-1a IM to fingolimod. These analytic methods may be useful in
evaluating treatment switch effects in clinical trials with extension data.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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.0/).1. Introduction
Prevention or delay of relapse is a major treatment goal of
disease-modifying therapy (DMT) for patients with multiple
sclerosis (MS) [1–3]. To evaluate efficacy, clinical trials of DMTs
in patients with MS routinely examine treatment effects on
relapse rates as a primary measure [4]. These trials are often
designed with a core treatment phase, wherein patients are
randomized to the investigational drug or control [5–11]; uponess article under the CC BY-NC-ND license
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the control groupmay be offered the opportunity to receive the
investigational drug during an extension phase [12–14].
From a study design perspective, it would be preferable to
prospectively re-randomize patients at the time of a treatment
switch to evaluate comparative outcomes after changing therapy.
This would entail some patients switching from the control to the
investigational treatment, some remaining on the control and
some continuing on with the investigational treatment. However,
even basic clinical trial designs inMS are operationally challenging
to execute, and such an approach is not common practice.
In the absence of controlled, parallel-group studies designed
to evaluate relapse-related outcomes after a DMT switch,
statistical methods originally developed to estimate treatment
effects in patients receiving alternative or rescue treatment in
clinical trials may have applicability in estimating the effects
of such a therapy switch based on the available clinical trial
and extension data [15]. Fingolimod is an oral, once-daily
sphingosine 1-phosphate receptor modulator approved (at a
dose of 0.5 mg/day) in theUnited States andmore than 70 other
countries for treatment of relapsing forms of MS. In the pivotal,
12-month, phase 3 Trial Assessing Injectable Interferon Versus
Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis
(TRANSFORMS; NCT00340834) study, fingolimod 0.5 or
1.25 mg daily demonstrated superiority to IFNβ-1a intramus-
cular (IM) in reducing the rate of relapse and extending the
time to first confirmed relapse [10]. In a 1-year extension of
TRANSFORMS, patients switching from IFNβ-1a IM treatment to
fingolimod 0.5 or 1.25 mg daily exhibited further within-group
annualized relapse rate (ARR) reductions compared with the
previous 12-month core phase, suggesting that switching to
fingolimod may provide additional clinical benefit in patients
receiving IFNβ-1a IM [13].
The current analysis used data from the IFNβ-1a IM treat-
ment group in the TRANSFORMS core study to predict the time
to first confirmed relapse had the patient not switched to
fingolimod during the extension phase and compared it with
the actual observed time to first confirmed relapse after
switching from IFNβ-1a IM to fingolimod.Fingolimod 0.5 mg
Fingolimod 1.25 mg
Core phase
(months 0–12)
IFNβ-1a IM
IFN=interferon; IM=intramuscular.
Fig. 1. Design of TRANSFORMS s2. Materials and methods
2.1. Study design
TRANSFORMS (N = 1292) was a 12-month, phase 3,
randomized, double-blind, double-dummy study of fingolimod
0.5 or 1.25 mg once daily versus IFNβ-1a IM 30 μg once weekly
[10] with an optional 1-year extension (Fig. 1) [13]. In the
extension study, patients receiving IFNβ-1a IM during the core
phase of the original study were randomly reassigned to
fingolimod 0.5 or 1.25 mg, and patients receiving fingolimod
during the core phase continued treatment at the previously
assigned dose. Key inclusion criteria were age 18 to 55 years
and diagnosis ofMS according to revisedMcDonald criteria [16]
with a relapsing–remitting course, ≥1 documented relapse in
the previous year or≥2 relapses in the previous 2 years, and an
Expanded Disability Status Scale (EDSS) score of 0 to 5.5 [17].
Relapsewas defined as new,worsening, or recurrent neurologic
symptoms≥30 days after onset of a preceding relapse without
fever or infection, with at least a half-point increase on the
EDSS, a ≥1-point increase in 2 functional system scores, or a
≥2-point increase in 1 functional system score (excluding
bowel/bladder and cognition).
The study was conducted in accordance with the Interna-
tional Conference on Harmonisation Guidelines for Good
Clinical Practice and the Declaration of Helsinki, and the study
protocol was approved by each institution. All patients gave
written informed consent.
2.2. Analysis
These post hoc analyses were based on 24-month data
(core + extension) for patients in the intent-to-treat popula-
tion. Log-linear regression models were employed to better
describe the relationship between time to first confirmed
relapse and treatment. The analyses started with an assump-
tion of a Weibull distribution for time to relapse, known as an
accelerated failure time model. The survival function S(t) was
estimated from the data set and plotted as log(− log(S(t)))Fingolimod 0.5 mg
Fingolimod 1.25 mg
Extension phase
(months 13–24)
Fingolimod 0.5 mg
(observed)
Modeled IFNβ-1a IM treatment
(estimated)
Fingolimod 1.25 mg
(observed)
Comparison
groups for
switch analysis
tudy and switch analysis.
Table 1
Weibull regression estimates for log (time to ﬁrst conﬁrmed relapse) during
core phase, intent-to-treat population.
Treatment Estimate Standard
error
95% CI P value
Model 1a
Fingolimod 0.5 mg 0.8462 0.1886 0.4765–1.2159 b0.0001
Fingolimod 1.25 mg 0.6021 0.1802 0.2489–0.9552 0.0008
IFNβ-1a IM
(reference)
0 NA NA NA
Model 2b
Fingolimod 0.5 mg 0.8095 0.1897 0.4377–1.1812 b0.0001
Fingolimod 1.25 mg 0.6010 0.1828 0.2428–0.9592 0.0010
IFNβ-1a IM
(reference)
0 NA NA NA
IFN=interferon; IM=intramuscular; NA=not applicable.
a Model 1 has treatment, country, number of relapses in the 2 years before
enrollment, and core baseline Expanded Disability Status Scale for patients as
explanatory variables.
b Model 2 has only treatment as the explanatory variable.
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justifying the Weibull distribution assumption. The LIFEREG
procedure within SAS software (SAS Institute Inc., Cary, NC)
was used to estimate the median time to relapse during core
phase. Predicted time to first confirmed relapse was calculated
using the log-linear regression model assuming Weibull
distribution for time to confirmed relapse, with treatment as
a lone explanatory variable (Model 1). A second model with
treatment, country, number of relapses in the 2 years before
enrollment in the core phase, and core phase baseline EDSS
score as explanatory variables was used for prediction of time
to first confirmed relapse and treatment comparisons. Statis-
tical comparisons of estimated median time to first relapse
were performed using z-test. No adjustment was made for
multiplicity.
The Branson and Whitehead switch model with iterative
parameter estimation [15] was used to estimate the time to
relapse during the extension phase in patients who switched
from IFNβ-1a IM to fingolimod 0.5 or 1.25 mg, had these
patients not switched treatment and instead remained on
IFNβ-1a IM. Each patient contributed a single event (i.e., the
first relapse) to the analysis, and the time originwas the time of
randomization. Themodel assumes that relapse rate is constant
except for the effects of switching to fingolimod, and the rate of
the “slowing down” of relapse was denoted by exp(−η). An
initial estimate of exp(−η) was obtained by comparing the
groups as randomized using a parametric accelerated failure
time model. For a given initial point estimate of exp(−η), the
estimated times to relapse of patients who switched from
IFNβ-1a IM to fingolimod 0.5 mg or 1.25 mgwere transformed
using the following formula:
Estimated time to relapse ¼ time to fingolimod switch
þ exp −η j
 
ðobserved time to relapse
−time to fingolimod switchÞ;
where j ¼ 1 or 2 to indicate 0:5 or 1:25 mg group:
Using these transformed times to relapse and the original
observed time to relapse for all other patients, the groups were
once again compared using the parametric survival analysis.
This analysis led to another estimate for exp(−η). This
estimate was used in a second transformation of the relapse
times of patients who switched treatment in the control group.
Once the entire processwas repeated several times, the value of
exp(−η) used in the transformation was close to the value
used in the previous iteration (within 10−5). At that point, the
procedure was considered to have converged.
Ratios of the observed time over the estimated time to
relapse were calculated; ratios N1 indicate a greater time to
relapse with fingolimod after switching from IFNβ-1a IM com-
pared with remaining on IFNβ-1a IM. Four sensitivity analyses
were performed. The first assumed a generalized gamma dis-
tribution in replacement of a Weibull distribution to test the
effects of nature of the data. The second sensitivity analysis
excluded the first 1.5, 3, and 6 months of core phase data to
account for long-lasting trends in the treatment effect. The third
excluded patients who did not enter the extension phase. The
fourth ignored relapses during the core phase for patients who
had relapsed in the extension phase.3. Results
The intent-to-treat population included 431 patients who
were randomized to IFNβ-1a IM during the core phase; 341
entered the extension,with 167 switching to fingolimod 0.5mg
and 174 switching to fingolimod 1.25 mg. After switching, 31
patients experienced a confirmed relapse, including 16 (9.5%)
who switched to fingolimod 0.5 mg and 15 (8.6%) who
switched to fingolimod 1.25 mg.
Estimates of Weibull regression parameters for treat-
ments based on core phase data are shown in Table 1. Results
obtained from the Weibull regression model demonstrated
that fingolimod 0.5 mg (P b 0.0001) and fingolimod 1.25 mg
(P = 0.0010) were associated with a longer time to first
confirmed relapse during the core phase compared with
IFNβ-1a IM (Fig. 2). The estimated median times to relapse
were 2.26 years for IFNβ-1a IM, 5.07 years for fingolimod
0.5 mg (P = 0.0026 vs. IFNβ-1a IM), and 4.11 years for
fingolimod 1.25 mg (P= 0.0113 vs. IFNβ-1a IM).
The estimated delay in time to relapse ranged from 3.1 to
184.4 days for patients switching from IFNβ-1a IM to
fingolimod 0.5 mg and from 5.5 to 142.8 days for patients
switching from IFNβ-1a IM to fingolimod 1.25 mg. The ratio of
the observed time to first confirmed relapse after the switch to
fingolimod to the estimated time to relapse if the patient
had remained on IFNβ-1a IM was 2.09 (95% CI, 1.45–3.04) for
patients switching from IFNβ-1a IM to fingolimod 0.5 mg and
1.84 (95%CI, 1.30–2.65) for patients switching from IFNβ-1a IM
to fingolimod 1.25 mg.
Sensitivity analyses of the observed time over the estimated
time to relapse demonstrated consistent results. Using the
generalized gamma distribution to relax the proportionality
assumption, fingolimod 0.5 mg (P b 0.0001) and fingolimod
1.25 mg (P= 0.0007) were superior to IFNβ-1a IM in delaying
the first confirmed relapse during the core phase. The estimated
median times to relapse were 1.95 years for IFNβ-1a IM,
4.18 years for fingolimod 0.5 mg (P = 0.0021 vs. IFNβ-1a IM),
and 3.49 years for fingolimod 1.25mg (P= 0.0075 vs. IFNβ-1a
IM; Fig. 3). Among the patients who experienced relapse after
switching, the estimated delay in time to relapse ranged from
3.3 to 195.0 days for patients switching to fingolimod 0.5 mg
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Fig. 2. Predicted time to first confirmed relapse calculated using core phase data andWeibull regressionmodel (a)* and Kaplan–Meier plot of time to first relapse in the
core phase (b).
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1.25 mg. Estimated ratios of observed time to relapse after
switching to the estimated time to relapse without switching
were 2.23 (95% CI, 1.50–3.32) for fingolimod 0.5 mg and
1.81 (95% CI, 1.19–2.70) for fingolimod 1.25 mg. FurtherPe
rc
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til
e
Predicted Time to Fir
0 4
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25th
IFN=interferon; IM=intramuscular.
*Gamma regression model with treatment as an explanatory variable. Error ba
Fig. 3. Predicted time to first confirmed relapse calculated using corsensitivity analysis excluding data from progressively longer
periods of the early core phase continued to indicate a delay in
time to first confirmed relapse associated with switching to
fingolimod versus remaining on IFNβ-1a IM (Table 2). By
excluding the patients who did not enter the extension phase,Fingolimod 0.5 mg
Fingolimod 1.25 mg
IFNβ-1a IM
st Confirmed Relapse, y
8 12
rs represent upper and lower bounds of time estimates.
e phase data and the generalized gamma regression model.*
Table 2
Sensitivity analysis of the ratio of the observed time to ﬁrst conﬁrmed relapse to
the estimated time to ﬁrst relapse had the patient not switched to ﬁngolimod.
Treatment group
Data exclusion
(core phase)
IFNβ-1a IM to
ﬁngolimod 0.5 mg
IFNβ-1a IM to
ﬁngolimod 1.25 mg
No exclusions 2.09 1.84
Months 0–1.5 1.80 1.72
Months 0–3 1.59 1.68
Months 0–6 1.36 1.42
IFN=interferon; IM=intramuscular.
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and 1.25 mg, respectively. Finally, by ignoring the relapses
during the core phase for patients who also had relapse in
extension phase (17, 19, and 40 patients in fingolimod 0.5 mg,
fingolimod 1.25 mg, and IFNβ-1a IM groups, respectively), the
estimated ratios of observed time to relapse after switching to
the estimated time to relapse without switching were 1.82 for
fingolimod 0.5 mg and 1.63 for fingolimod 1.25 mg.
4. Discussion
In this analysis of the TRANSFORMS trial and extension
data, the median time to first relapse was approximately
doubled in patients treated with fingolimod 0.5 or 1.25 mg
versus IFNβ-1a IM during the core phase; during the extension
phase, the observed time to first confirmed relapse after
switching from IFNβ-1a IM to fingolimod 0.5 or 1.25 mg was
also approximately double the estimated time to relapse had
the patient remained on IFNβ-1a IM. These results support the
superior efficacy of fingolimod 0.5 and 1.25 mg over IFNβ-1a
IM in terms of time to first confirmed relapse during the 1-year
core phase and the positive impact of switching from
fingolimod to IFNβ-1a IM on time to relapse during the
1-year extension phase. These results further complement
previous findings demonstrating a benefit of switching therapy
from IFNβ-1a IM to fingolimod [18]. Among patients who
switched from IFNβ-1a IM to fingolimod 0.5 or 1.25 mg at the
start of the extension phase, ARRs were reduced by 30% and
36%, respectively, during the 12-month extension period
compared with the previous 12-month core phase [13].
Furthermore, subgroup analysis of the TRANSFORMS core
phase data showed that among patients with a history of
IFNβ treatment, fingolimod 0.5 and 1.25 mg significantly
reduced ARR by approximately 58% and 39%, respectively,
compared with IFNβ-1a IM [18].
Previous analyses of TRANSFORMS core phase data support
the idea that the effect of fingolimod on relapse reduction is
most apparent in patients with disease activity despite prior
treatment with other DMTs [19]. In the proposed model,
estimated time to relapse was delayed in all 31 patients who
experienced a relapse after switching to fingolimod, compared
with if they had continued to receive IFNβ-1a IM. However, the
results were based on a modeling approach with an assump-
tion of delay in relapse with switching. Thus, it should not be
assumed that every patient switching to fingolimod would
experience a delay in relapse compared with continued
treatment with IFNβ-1a IM. Although the estimated delay in
relapse occurrence ranged from 3 to 184 days for patients
switching to the approved 0.5mgdose of fingolimod, it was notpossible to analyze the delay with respect to reason for
switching because all patients who received IFNβ-1a IM during
the core phase were switched to fingolimod.
To directly address switching outcomes, a preferred study
design would include double-blinded re-randomization at the
time of a switch, resulting in patients continuing on experi-
mental treatment, switching from control to experimental
treatment, or remaining on control treatment. The current
modeling of TRANSFORMS core and extension trial data
allowed for retrospective evaluation of the effects of remaining
on IFNβ-1a IM in the absence of a prospectively designed,
double-blinded switch study. This represents one of the earliest
applications of the Branson and Whitehead switch model to
examine treatment effects in this manner, and may provide a
valuablemeans to evaluate trial extension switch data for other
MS therapies by allowing estimation of the treatment benefit in
trials that include a rescue treatment for patients in the placebo
group for ethical reasons.
Key limitations to this analysis are the 24-month study
duration and assumptions inherent in the Branson and
Whitehead model that minimize the potential effects of some
typical features of trial populations on the model. The model
assumes that relapse rate is constant except for the effects of
switching, but long-term studies have shown that clinical trial
populations have slowly declining relapse rates during contin-
ued follow-up, regardless of treatment [20,21]. However, the
natural decline in relapse rates during a single year of follow-up
and the impact on the rate ratio between groups is likely to
have a minimal effect in the assumed model. As suggested by
the findings of the sensitivity analysis, the natural decline in
relapse ratewas not of a great enoughmagnitude to explain the
doubling of time to first confirmed relapse seen after switching
to fingolimod in the current analysis.
5. Conclusions
In summary, this report suggests that switching from
IFNβ-1a IM to fingolimod 0.5 or 1.25 mg will delay relapse
compared with remaining on IFNβ-1a IM. These analytic
methods may help clinicians better understand the treatment
effects observed after switching therapies, andmay be useful in
evaluating trial extension switch data for other MS treatments.
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